The presence of anti-SSA/Ro52 and anti-SSA/Ro60 was not significantly different between the two groups; however, when combined with ANA titers, we observed that patients in the thrombocytopenia group were more likely to have positive anti-SSA/Ro60 and ANA titers < 1:320 than those in the control group (P = 0.018). This evidence concerns the gene TRIM21 and Thrombocytopenia.